Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and +0.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?